Vor Bio licenses telitacicept from RemeGen for $125M upfront, raises $175M PIPE, appoints new CEO

Vor Biopharma Inc.

License deal: Vor Bio gets ex-China rights to telitacicept (global Phase 3 for gMG) for $125M upfront ($45M cash + $80M warrants); up to $4B+ milestones plus royalties.
Private Placement: $175M gross from pre-funded warrants to buy 700M shares at $0.25/warrant; closing expected June 27, 2025.
CEO change: Robert Ang resigned; Jean-Paul Kress (ex-MorphoSys CEO) appointed CEO and Chairman. Dr. Ang stays as advisor through October.
Cambridge lease terminated: $8.5M termination fee paid; $2.4M letter of credit to be returned. Lease was set to expire in 2030.
Stockholders representing ~63% voting power signed support agreements to approve share issuance and charter amendment.

item 1.01 item 1.02 item 3.02 item 5.02 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.